Idiopathic pulmonary fibrosis
You don't need to be Editor-In-Chief to add or edit content to WikiDoc. You can begin to add to or edit text on this WikiDoc page by clicking on the edit button at the top of this page. Next enter or edit the information that you would like to appear here. Once you are done editing, scroll down and click the Save page button at the bottom of the page.
| Idiopathic pulmonary fibrosis Classification and external resources | |
 | |
|---|---|
| Extensive lung fibrosis from usual interstitial pneumonitis | |
| ICD-9 | 516.3 |
| OMIM | 178500 |
| DiseasesDB | 4815 |
| MedlinePlus | 000069 |
| eMedicine | radio/873 |
| MeSH | D011658 |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Phone:617-525-6884
Please Take Over This Page and Apply to be Editor-In-Chief for this topic: There can be one or more than one Editor-In-Chief. You may also apply to be an Associate Editor-In-Chief of one of the subtopics below. Please mail us [2] to indicate your interest in serving either as an Editor-In-Chief of the entire topic or as an Associate Editor-In-Chief for a subtopic. Please be sure to attach your CV and or biographical sketch.
Idiopathic Pulmonary Fibrosis (IPF), also known as Cryptogenic fibrosing alveolitis, is a chronic progressive interstitial lung disease of unknown etiology. It is one of the two classic interstitial lung diseases, the other being sarcoidosis.[1]
More specifically, IPF is defined as a distinctive type of chronic fibrosing interstitial pneumonia of unknown cause associated with a histological pattern of usual interstitial pneumonia (UIP).[1]
Etiology
Pulmonary fibrosis has often been called an autoimmune disease. However, it is perhaps better characterized as an abnormal and excessive deposition of fibrotic tissue in the pulmonary interstitium with minimal associated inflammation.[1] Autoantibodies, a hallmark of autoimmune diseases, are found in a minority of patients with truly idiopathic pulmonary fibrosis. Moreover, many autoimmune diseases associated with "pulmonary fibrosis", such as scleroderma, are more frequently associated with a related but more inflammatory disease, nonspecific interstitial pneumonitis.[1] It is associated with smoking[1] and exhibits some dependency on the amount of smoking.[1]
Classification
Idiopathic pulmonary fibrosis is a type of idiopathic interstitial pneumonia (IIP), which in turn is a type (or group) of interstitial lung diseases.[1]
Idiopathic interstitial pneumonias include:
- idiopathic pulmonary fibrosis (IPF) (the most common)
- nonspecific interstitial pneumonia
- cryptogenic organizing pneumonia
- acute interstitial pneumonia
- respiratory bronchiolitis-associated interstitial lung disease
- desquamative interstitial pneumonia
- lymphoid interstitial pneumonia
Clinical features
Idiopathic Pulmonary Fibrosis is slightly more common in males and usually presents in patients greater than 50 years of age. Average survival from time of diagnosis varies between 2.5 and 3.5 years, depending on severity, although some patients live greater than 10 years.[1]
Symptoms are gradual in onset. The most common are dyspnea (difficulty breathing), but also include nonproductive cough, clubbing (a disfigurement of the fingers), and crackles (crackling sound in lungs during inhalation).[1] It should be noted that these features are non-specific and can occur in a spectrum of other pulmonary disorders.
The key issue facing clinicians is whether the presenting history, symptoms/signs, radiology, and pulmonary function testing are collectively in keeping with the diagnosis of IPF (which carries the relatively poor prognosis described above) or whether the findings are due to another process. It has long been recognized that patients with interstitial lung disease related to asbestos exposure, drugs (particularly chemotherapeutic agents), a connective tissue disease, or other diseases may have features that are difficult to distinguish from IPF. Important differential diagnostic considerations include asbestosis; interstitial lung disease related to scleroderma, mixed connective tissue disease, or rheumatoid arthritis; advanced sarcoidosis, hypersensitivity pneumonitis, or Langerhans cell histiocytosis; chronic pulmonary aspiration; radiation-induced fibrosis; as well as previous therapy with cyclophosphamide, nitrofurantoin, methotrexate, and other drugs.
When diagnostic uncertainty remains, a surgical lung biopsy may be required to establish the diagnosis. Generally, lung biopsy is only undertaken when it is deemed that its risks are outweighed by the potential benefits of identifying a disease process that may be amenable to a treatment that the patient would likely be able to tolerate.
The 2002 American Thoracic Society/European Respiratory Society Consensus Guidelines on the Idiopathic Interstitial Pneumonias have formalized criteria for situations in which it is possible to establish the diagnosis of IPF without a lung biopsy.[1]
Radiology
Plain chest x-rays reveal decreased lung volumes, typically with prominent reticular interstitial markings near the lung bases and posteriorly. Honeycombing, a pattern of dense fibrosis characterized by multiple tiny air-filled spaces located at the bases of the lungs, is frequently seen in advanced cases. In less severe cases, these changes may not be evident on a plain chest film.
High-resolution CT scans of the chest demonstrate a symmetrical pattern of bibasilar, peripheral, and subpleural intralobular septal thickening, fibrotic changes, honeycombing, and traction bronchiectasis and bronchiolectasis. There may be associated ground glass opacity of the lungs but these changes are relatively minor in comparison with the fibrotic changes.[1]
Pulmonary function tests
Spirometry classically reveals a reduction in the vital capacity with either a proportionate reduction in airflows, or increased airflows for the observed vital capacity. The latter finding reflects the increased lung stiffness (reduced lung compliance) associated with pulmonary fibrosis, which leads to increased lung elastic recoil.[1]
Measurement of static lung volumes using body plethysmography or other techniques typically reveals reduced lung volumes (restriction). This reflects the difficulty encountered in inflating the fibrotic lungs.
The diffusing capacity for carbon monoxide (DLCO) is invariably reduced in IPF and may be the only abnormality in mild or early disease. Its impairment underlies the propensity of patients with IPF to exhibit oxygen desaturation with exercise.
Histology
Histologic specimens for the diagnosis of IPF must be large enough that the pathologist can comment on the underlying lung architecture.
Small biopsies, such as those obtained via transbronchial lung biopsy (performed during bronchoscopy) are generally not sufficient for this purpose. Hence, larger biopsies obtained surgically via a thoracotomy or thoracoscopy are usually necessary.[1]
The histological pattern of fibrosis associated with IPF is referred to as usual interstitial pneumonia (UIP).
Although UIP is required for the diagnosis of IPF, it can be seen in other diseases as well.[1]
Key features of UIP include fibroblast foci, a pattern of temporal heterogeneity, dense interstitial fibrosis in a paraseptal and subpleural distribution, and a relatively mild or minor component of interstitial chronic inflammation.[1] To help narrow the differential diagnosis, an absence of significant granulomatous inflammation, microorganisms, eosinophils, and asbestos bodies is required.
Diagnosis
The diagnosis of IPF can be made by demonstrating UIP pattern on lung biopsy in a patient without clinical features suggesting an alternate diagnosis (see clinical features, above). Establishing the diagnosis of IPF without a lung biopsy has been shown to be reliable when expert clinicians and radiologists concur that the presenting features are typical of IPF.[1] Based on this evidence, the 2002 ATS/ERS Multidisciplinary Consensus Statement on the Idiopathic Interstitial Pneumonias proposes the following criteria for establishing the diagnosis of IPF without a lung biopsy:[1]
Major criteria (all 4 required):
- Exclusion of other known causes of interstitial lung disease (drugs, exposures, connective tissue diseases)
- Abnormal pulmonary function tests with evidence of restriction (reduced vital capacity) and impaired gas exchange (pO2, p(A-a)O2, DLCO)
- Bibasilar reticular abnormalities with minimal ground glass on high-resolution CT scans
- Transbronchial lung biopsy or bronchoalveolar lavage (BAL) showing no features to support an alternative diagnosis
Minor criteria (3 of 4 required):
- Age > 50
- Insidious onset of otherwise unexplained exertional dyspnea
- Duration of illness > 3 months
- Bibasilar inspiratory crackles
Treatment
There is currently no consensus on the treatment of IPF. Hence, none of what follows should be taken as specific advice regarding therapy, as the latter is a decision that must be made on a case-by-case basis in individual patients.[1]
There is a lack of large, randomized placebo-controlled trials of therapy for IPF. Moreover, many of the earlier studies were based on the hypothesis that IPF is an inflammatory disorder, and hence studied anti-inflammatory agents such as corticosteroids. Another problem has been that studies conducted prior to the more recent classification of idiopathic interstitial pneumonias failed to distinguish IPF/UIP from NSIP in particular. Hence, many patients with arguably more steroid-responsive diseases were included in earlier studies, confounding the interpretation of their results.[1]
Small early studies demonstrated that the combination of prednisone with either cyclophosphamide or azathioprine over many months had very modest, if any, beneficial effect in IPF, and were associated with substantial adverse effects (predominantly myelotoxicity). Other treatments studied have included interferon gamma-1b and the antifibrotic agent pirfenidone. While neither drug has been shown to have substantial benefits over time, both are currently being studied in patients with IPF. Finally, the addition of the antioxidant N-acetylcysteine to prednisone and azathioprine produced a slight benefit in terms of FVC and DLCO over 12 months of follow up. However, the major benefit appeared to be prevention of the myelotoxicity associated with azathioprine.[1]
References
External links
- PILOTforIPF.org - Pulmonary Fibrosis Identification: Lessons for Optimizing Treatment
- NCBI OMIM #178500: Idiopathic Pulmonary Fibrosis
- American Thoracic Society/European Respiratory Society International Multidisciplinary Consensus Classification of the Idiopathic Interstitial Pneumonias , American Journal of Respiratory and Critical Care Medicine , Volume 165, Number 2, January 2002, 277-304.
- University of Cincinnati Interstitial Lung Disease Center
- Dorothy P. and Richard P. Simmons Center for Interstitial Lung Diseases
- PA-IPF - The Pennsylvania Idiopathic Pulmonary Fibrosis State Registry
- Clinical trials in IPF
- UCSF Interstitial Lung Disease Center of Excellence
Acknowledgement and Attribution Regarding Sources of Content
Some of the initial content on this page may be incorporated in part from copyleft sources in the public domain including wikis such as Wikipedia and AskDrWiki. Drug information for patients came from the The National Library of Medicine. Infectious disease information may have come from the Centers for Disease Control (CDC). Differential Diagnoses are drawn from clinicians as well as an amalgamation of 3 sources: 1.The Disease Database; 2. Kahan, Scott, Smith, Ellen G. In A Page: Signs and Symptoms. Malden, Massachusetts: Blackwell Publishing, 2004:3; 3. Sailer, Christian, Wasner, Susanne. Differential Diagnosis Pocket. Hermosa Beach, CA: Borm Bruckmeir Publishing LLC, 2002:7 .
